肽受体放射性核素治疗(PRRT)在欧洲神经内分泌肿瘤学会(ENETS)3级(G3)神经内分泌肿瘤(NEN)中的应用——单中心回顾性分析
该单中心回顾性分析评估了PRRT在28例G3 NEN患者中的疗效,其中Ki-67≤55%者22例。全组中位无进展生存期(PFS)为9个月,中位总生存期(OS)为19个月;Ki-67≤55%组中位PFS为12个月、中位OS为46个月,Ki-67>55%组中位PFS为4个月、中位OS为7个月。PRRT在G3 NEN中实现了具有临床意义的疾病控制,毒性可接受。
要点
- 全组28例G3 NEN患者PRRT后中位PFS为9个月,中位OS为19个月。
- Ki-67≤55%组(22例)中位PFS 12个月、中位OS 46个月,优于Ki-67>55%组(6例)的4个月和7个月。
- PRRT后3个月CT评估疾病控制率(DCR)为74%,其中部分缓解(PR)35%(8/23)、疾病稳定(SD)39%(9/23)。
核心结论
- PRRT在G3 NEN中实现了具有临床意义的疾病控制,且毒性可接受。
研究设计与样本
- 单中心回顾性分析,纳入28例G3 NEN患者(男性17例,年龄16-78岁,Ki-67≤55%者22例)。
- 采用Kaplan-Meier法估算自PRRT开始计算的无进展生存期(PFS)和总生存期(OS),并对Ki-67≤55%与>55%患者进行亚组分析。
- PRRT后3个月评估解剖学疗效(RECIST 1.1)和毒性;疾病控制率(DCR)定义为既往进展患者中完全缓解(CR)、部分缓解(PR)和疾病稳定(SD)之和。
主要发现
- 28例中17例为胰腺、5例为小肠、3例为大肠、2例为支气管、1例为原发灶不明;25/28例治疗前有显著FDG高摄取病灶。
- 多数患者接受177Lu-DOTA-octreotate治疗(中位累积活度24.4 GBq,中位4个周期);20例接受放疗增敏化疗;89%因疾病进展接受治疗,79%既往接受过化疗。
- 中位随访29个月;全组中位PFS为9个月,16例死亡(Ki-67≤55%组11例,Ki-67>55%组5例),中位OS为19个月。
- Ki-67≤55%组(N=22)中位PFS为12个月、中位OS为46个月;Ki-67>55%组(N=6)中位PFS为4个月、中位OS为7个月。
- PRRT后3个月CT评估DCR为74%,PR 35%(8/23)、SD 39%(9/23);11例因缓解后疾病复发接受进一步PRRT,5例出现不一致FDG高摄取病灶进展并转诊接受靶向治疗/化疗;3级和4级淋巴细胞减少各5例、血小板减少各5例,未见治疗相关肾或肝毒性。
关键数值与推荐
- DCR定义为既往进展患者中CR、PR和SD之和。
- 解剖学疗效采用RECIST 1.1评估。
- 亚组分析按Ki-67≤55%和>55%划分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Grade 3 NENs are aggressive tumours with poor prognosis. PRRT+/- radiosensitising chemotherapy is a potential treatment for disease with high somatostatin receptor (SSTR) expression without spatially discordant FDG-avid disease. We retrospectively evaluated the efficacy of PRRT in G3 NEN. METHODS: Kaplan-Meier estimation was used to determine progression-free survival (PFS) and overall survival (OS) defined from start of PRRT. Subgroup analysis was performed for patients with Ki-67 ≤ 55% and >55%. Anatomical response (RECIST 1.1) and toxicity 3 months after PRRT was determined. Disease control rate (DCR) was defined as complete response (CR), partial response (PR) and stable disease (SD) of those with prior progression. RESULTS: 28 patients (M = 17; age 16-78 years; Ki-67 ≤ 55% = 22) were reviewed. 17 patients had pancreatic, 5 small bowel, 3 large bowel, 2 bronchial and 1 unknown primary disease. 25/28 had significant FDG-avid disease prior to treatment. Most had 177Lu-DOTA-octreotate (median cumulative activity 24.4 GBq, median 4 cycles). Twenty patients had radiosensitising chemotherapy. 89% were treated for disease progression; 79% after prior chemotherapy. Median follow-up was 29 months. The median PFS was 9 months for all patients. 16 patients died (Ki-67 ≤ 55% = 11; Ki-67 > 55% = 5) with median OS of 19 months. For Ki-67 ≤ 55% (N = 22), the median PFS was 12 months and median OS 46 months. For Ki-67 > 55% (N = 6), the median PFS was 4 months and median OS 7 months. On CT imaging, DCR at 3 months post-PRRT was 74%, 35% (8/23) PR and 39% (9/23) SD. Eleven patients received further PRRT due to recrudescent disease after response. Five patients developed progression of discordant FDG-avid disease and were referred for targeted therapy/chemotherapy. Grade 3 and 4 lymphopenia and thrombocytopenia occurred in five and five patients, respectively. No renal or liver toxicity related to treatment was seen. CONCLUSIONS: PRRT achieves clinically relevant disease control with acceptable toxicity in G3 NENs.
引用
- Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2017. PMID: 28894897. doi:10.1007/s00259-017-3821-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。